Surgical Lung Biopsy for Diffuse Pulmonary Disease: Experience of 196 Patients
Resource
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY v.129 n.5 pp.984-990
Journal
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Journal Volume
v.129
Journal Issue
n.5
Pages
984-990
Date Issued
2005
Date
2005
Author(s)
LEE, YUNG-CHIE
WU, CHEN-TU
Abstract
Objective Surgical lung biopsy is considered the final method of diagnostic modality in patients with undiagnosed diffuse pulmonary disease . Nevertheless, the effect of surgical lung biopsy on the diagnosis, treatment, and outcome of the patient still remains controversial. This study reviewed the experiences of surgical lung biopsies in 196 consecutive patients during the past 7 years. Methods Surgical lung biopsy was performed after achievement of general anesthesia through video- assisted thoracoscopic surgery or a 7-cm minithoracotomy. Biopsy specimens were swabbed for aerobic and anaerobic bacterial, fungal, and mycobacterial cultures. The sections of specimens were routinely stained with hematoxylin and eosin, and acid-fast, Gomori methenamine silver, Gram stain, or other special stains were added if necessary. Results The pathologic diagnosis after surgical lung biopsy included infection (30. 6% ), interstitial pneumonia or fibrosis (21.9%), diffuse alveolar damage (17 .3%), neoplasm (13.3%), autoimmune diseases (8.2%), and others (8.2%). After surgical lung biopsy, 165 (84.2%) patients had changes in their therapy, 124 (63.3%) patients had clinical improvement of their conditions , and 119 (60.7%) patients survived to hospital discharge. Comparison between immunocompromised and immunocompetent patients showed that diagnosis of infection was significantly higher (P < .01) in the former group (41.2 % vs 20.2%). In addition, there was no significant difference in the distribution of diagnosis and rate of change in therapy between the respiratory failure and nonrespiratory failure groups. However, the rates of response to therapy and patient survival were significantly lower in the respiratory failure group (51.2% and 41.5%) than in the nonrespiratory failure group (71.9% and 78.1%, P < .05). There was no surgical mortality directly related to the procedure. The surgical morbidity rate was 6.6%. Conclusion Surgical lung biopsy is a safe and accurate diagnostic tool for diffuse pulmonary disease. For a large proportion of the patients, change of therapy and then clinical improvement can be achieved after surgical lung biopsy. Surgical lung biopsy should be considered earlier in patients with undiagnosed diffuse pulmonary disease, especially when the respiratory condition is deteriorating.
Type
journal article